NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

DCVax-L is the biggest revolution in medicine since the invention of antibiotics

You still have doubt about the above claim? That's unfortunate. Have you read some of Dr. Liau's papers or watched some of her presentations?

Don't look down on this stock message board. Thousands of people with various backgrounds have been vetting this investment from every possible angle. It is the most vetted stock on Wall Street. I had been eavesdropping all the discussions and picked up tons of useful info. Still do even today. Had those bashers not tried to rip off my investment through lies and falsifications, I would have kept eavesdropping.

I don't know when the approval news will come. Last time Merck gave not positive forward forecast and its value was vaporized $30b? Is September 15 the PDUFA of Roche SC Tecentriq? December 25 is the PDUFA of BMS SC Opdivo for all indications currently covered by IV Opdivo.

Merck has been shy about its SC keytruda trial. I don't know how long Merck can keep being shy since the approval of the SC CIs from its two competitors will certainly deal a blow to Merck's sp.






I want to know the share price too. Does BPs' sudden enthusiasm in ADCs have anything to do with DCVax-L? If it does, the announcement of franchise agreements with even some of the BPs after the approval will send the sp to the stratosphere immediately.

All BPs are in precision oncology business.

Amgen
Amgen piles $2B more into pharma's ADC rush in Synaffix pact
https://fiercebiotech.com/biotech/amgen-piles-2-billion-more-pharmas-adc-rush-synaffix-pact

Amgen and Hummingbird to use technologies from Synaffix to develop novel ADCs
https://ppf.eu/en/insights/biotech-market/january-2023-biotechnology-review-of-news-from-the-most-innovative-therapeutic-ar/amgen-and-hummingbird-to-use-technologies-from-synaffix-to-develop-novel-adcs

LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
https://businesswire.com/news/home/20221223005034/en/LegoChem-Biosciences-and-Amgen-Enter-into-a-Multi-Target-Research-Collaboration-and-License-Agreement-for-the-Development-of-Antibody-Drug-Conjugates

Merck
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
https://merck.com/news/merck-and-kelun-biotech-announce-exclusive-license-and-collaboration-agreement-for-seven-investigational-antibody-drug-conjugate-candidates-for-the-treatment-of-cancer/

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
https://merck.com/news/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/

Merck & Co. signs $208M deal to acquire startup in bid to improve ADC safety
https://fiercebiotech.com/biotech/merck-co-signs-280m-deal-acquire-startup-bid-improve-adc-safety

AstraZeneca

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore
https://astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-manufacture-adcs-in-singapore.html

AstraZeneca, spying post-BCMA big bucks, pays $55M for ADC to join peers in hot cancer space
https://fiercebiotech.com/biotech/astrazeneca-spying-post-bcma-big-bucks-pays-55m-adc-join-peers-hot-cancer-space

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
https://astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-fusion.html

AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
https://fiercebiotech.com/biotech/astrazeneca-doubles-down-hot-cancer-target-paying-63m-adc-months-after-bispecific-deal

Roche
Roche Signs Potential $1B ADC Cancer Deal with China’s MediLink
https://biospace.com/roche-signs-potential-1b-adc-deal-with-china-s-medilink

JPM24: Roche's pharma BD chief explains renewed ADC interest but is spoilt for choice
https://fiercebiotech.com/biotech/jpm24-roches-pharma-bd-chief-explains-renewed-adc-interest-and-invisible-bar-all-dealmaking

Abbvie
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field
https://fiercepharma.com/pharma/abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field

J&J
J&J to acquire ADC drug developer Ambrx for $2B
https://biopharmadive.com/news/johnson-johnson-ambrx-acquire-deal-antibody-drug-conjugate-prostate/703867/

J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets
https://fiercebiotech.com/biotech/j-j-s-janssen-inks-1b-biobucks-pact-for-mersana-s-adc-tech-for-three-targets

J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem
https://pharmaceutical-technology.com/news/jj-jumps-on-adc-train-signs-1-7bn-licensing-deal-with-legochem/

Eli Lilly
$470 million:Lilly quietly completes purchase of ADC player Emergence Therapeutics
https://linkedin.com/pulse/470-millionlilly-quietly-completes-purchase-adc-player-emergence/

Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing
https://biospace.com/myricx-bio-raises-115m-in-series-a-to-advance-adc-with-lilly-and-novo-backing

Lilly makes another ADC play, buying Mablink
https://pharmaphorum.com/news/lilly-makes-another-adc-play-buying-mablink

Gilead
Gilead signs antibody deal with Biocytogen amid ADC buzz
https://pharmaceutical-technology.com/news/gilead-signs-antibody-deal-with-biocytogen-amid-adc-buzz/

BMS
BMS pays $800M upfront for antibody-drug conjugate, opening new front in Merck rivalry
https://fiercebiotech.com/biotech/bristol-myers-pays-800m-upfront-antibody-drug-conjugate-opening-new-front-merck-co-rivalry

BMS and SystImmune enter $8.4bn ADC development deal
https://pharmaceutical-technology.com/news/bms-systimmune-adc-deal/

Bristol Myers pays $23M to develop solid tumor ADCs based on Tubulis' toxicity-taming technology
https://fiercebiotech.com/biotech/bristol-myers-pays-23m-develop-solid-tumor-adcs-based-tubulis-toxicity-taming-technology

Fierce Pharma Asia—BMS’ $8.4B ADC bet; China’s reimbursement update; FDA’s CAR-T roadblock
https://fiercepharma.com/pharma/bms-huge-adc-bet-china-nrdl-update-fda-car-t-roadblock

Takeda

Takeda to Acquire Exclusive Development and Marketing License of ImmunoGen’s Mirvetuximab Soravtansine-gynx in Japan
https://takeda.com/ja-jp/announcements/2023/mirvetuximab_soravtansine-gynx_en/

ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan
https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-collaboration-takeda-develop-and

Takeda opens 4th front in assault on celiac, tapping Innate to develop antibody-drug conjugates
https://fiercebiotech.com/biotech/takeda-opens-4th-front-assault-celiac-tapping-innate-develop-antibody-drug-conjugates

GSK
GSK bets $1.3B on Mersana's preclinical ADC and chance to expand portfolio beyond Blenrep
https://fiercebiotech.com/biotech/gsk-bets-13b-mersanas-preclinical-adc-chance-expand-portfolio-beyond-blenrep

In 2nd big ADC deal of the day, GSK inks $1.4B pact for Hansoh gynecology cancer asset
https://fiercebiotech.com/biotech/2nd-big-adc-deal-day-gsk-inks-2b-pact-hansoh-gynecology-cancer-asset